Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains ‘Hold’ Rating
With significant hedge fund interest and a share price under $10, Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc. (RCKT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Maverick Capital Lee Ainslie | 8,363,813 | $20,491,342 | +61% | 0.31% |
| 2. | Suvretta Capital Management Aaron Cowen | 4,143,333 | $10,151,166 | +19% | 0.31% |
| 3. | BioImpact Capital Mpm Capital | 3,903,081 | $9,562,548 | +142% | 1.66% |
| 4. | Millennium Management Israel Englander | 2,348,837 | $5,754,651 | +215% | 0% |
| 5. | Newtyn Management Noah Levy And Eugene Dozortsev | 2,000,000 | $4,900,000 | 0.74% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.41 | 10,000 | $34,100.00 | 40,000 | 2025-08-27 | Filing | |
| $5.08 | 20,000 | $101,600.00 | 792,680 | 2025-04-10 | Filing | |
| $4.70 | 21,099 | $99,165.30 | 26,774 | 2025-04-09 | Filing | |
| $14.75 | 1,355,932 | $19,999,997.00 | 17,628,567 | 2022-10-06 | Filing | |
| $17.34 | 22,000 | $381,513.00 | 517,639 | 2022-02-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.00 | 361 | $1,081.56 | 55,924 | 2025-08-19 | Filing | |
| $3.07 | 699 | $2,142.44 | 56,285 | 2025-08-18 | Filing | |
| $3.00 | 805 | $2,411.78 | 221,609 | 2025-08-19 | Filing | |
| $3.07 | 1,680 | $5,149.20 | 222,414 | 2025-08-18 | Filing | |
| $3.00 | 588 | $1,761.65 | 135,462 | 2025-08-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 35,816 | $116,760 | 0% | |
| 2. | 27,709 | $90,331 | 0.01% | |
| 3. | 14,650 | $47,759 | 0% | |
| 4. | 2,526 | $8,235 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the most promising penny stocks under $5.
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Rocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene Therapies
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) Stock, Slashes PT
On May 30, Evercore ISI downgraded Rocket Pharmaceuticals, Inc.
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease.